ArticleEMBO reports2026
Enterovirus A71 3AB protein facilitates immune evasion by blocking cGAS recognition of mtDNA.
Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Mitochondrial DNA (mtDNA) is a powerful stimulator of the innate immune system and has been shown to trigger cytosolic DNA-sensing signaling during picornavirus infection. In this study, we observe that EV-A71 infection induces mitochondrial damage and leads to the release of mtDNA into the cytoplasm, which was mediated by the viral 2B protein. Despite this release, EV-A71 effectively suppresses the cGAS-STING-mediated type I interferon (IFN-I) response. We identify the nonstructural protein 3AB as a key viral antagonist of mtDNA sensing. Mechanistically, 3AB directly binds cytosolic mtDNA and disrupts cGAS-DNA phase separation, thereby suppressing cGAS-STING-dependent antiviral signaling. The immunosuppressive function of 3AB depends on the "3B + 7" region, with mutations impairing its mtDNA binding and IFN-I suppression. Moreover, the 3AB proteins from coxsackievirus A9 (CVA9) and A16 (CVA16) also exhibit mtDNA-binding ability. This study reveals a novel immune evasion strategy by blocking mtDNA-triggered immune signaling, providing new insights into the interplay between viral infection and mitochondrial immune defense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.